Abstract: Methods and systems for designing, testing, and validating genome designs based on rules or constraints or conditions or parameters or features and scoring are described herein.
Type:
Grant
Filed:
June 15, 2017
Date of Patent:
June 14, 2022
Assignee:
President and Fellows of Harvard College
Inventors:
Gleb Kuznetsov, Marc J. Lajoie, Matthieu M. Landon, Michael G. Napolitano, Daniel Bryan Goodman, Christopher J. Gregg, George M. Church, Nili Ostrov
Abstract: The present invention relates to compositions such as cleaning compositions comprising a mix of enzymes. The invention further relates, use of compositions comprising such enzymes in cleaning processes.
Abstract: Provided herein are compositions and methods for increasing editing efficiency of a target nucleic acid. A composition may comprise a guide nucleic acid, a Cas9 nickase, or a reverse transcriptase. The reverse transcriptase may be fused to the Cas9 nickase. The reverse transcriptase may heterodimerize with the Cas9 nickase. The reverse transcriptase may bind to a guide nucleic acid. The reverse transcriptase may be engineered to increase processivity. The guide nucleic acid may be engineered to facilitate synthesis or editing of a sequence. The guide nucleic acid, Cas9 nickase, and reverse transcriptase may be engineered to fit within AAV vectors. The guide nucleic acid may comprise a region that binds to another region on the guide nucleic acid to improve gene editing.
Abstract: The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.
Type:
Grant
Filed:
November 28, 2018
Date of Patent:
May 24, 2022
Assignee:
University of Vermont and State Agricultural College
Inventors:
Christopher Francklyn, Karen M. Lounsbury, Tamara Williams
Abstract: The invention relates to polypeptides having hydrolytic activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
Abstract: The present application relates, in some aspects, to the development of an assay that uses cell survival and/or cell viability as a phenotypic identifier to positively select for agents that destabilize a protein of interest.
Abstract: The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase (EC 1.2.1.10) activity. The invention further relates to the use of a cell according to the invention in the preparation of ethanol.
Type:
Grant
Filed:
February 15, 2021
Date of Patent:
May 10, 2022
Assignee:
DSM IP ASSETS B.V.
Inventors:
Jacobus Thomas Pronk, Antonius Jeroen Adriaan Van Maris, Victor Gabriel Guadalupe Medina
Abstract: Herein is reported a polypeptide comprising the amino acid sequence of SEQ ID NO: 38 as sole Listeria monocytogenes derived polypeptide and its use in conjugating polypeptides.
Abstract: The present invention relates to an MG53 mutant, wherein the MG53 mutant is identical to the amino acid sequence of a wild-type MG53 except for at least one serine in the coiled-coil-SPRY region of the wild-type MG53, which is deleted and/or mutated into any other non-serine or non-threonine amino acid(s). The present invention also relates to a pharmaceutical composition comprising the MG53 mutant, a nucleic acid encoding the MG53 mutant, a method for preparing the MG53 mutant, use of the MG53 mutant in the manufacture of a medicament for treating heart diseases, diabetic cerebrovascular diseases, diabetic ocular complications, diabetic neuropathy, diabetic foot, kidney diseases, and diseases associated with cellular and/or tissue damage. In particular, the MG53 mutant of the present invention may avoid or reduce metabolic side effects, such as, insulin resistance, obesity, diabetes, hypertension, dyslipidemia, etc.
Type:
Grant
Filed:
January 30, 2019
Date of Patent:
April 19, 2022
Assignee:
Hope Medicine (Nanjing) Co., Ltd.
Inventors:
Rui-ping Xiao, Fengxiang Lu, Yan Zhang, Sile Guo
Abstract: Provided herein are methods and systems for the production of a nanolipoprotein particle (NLP) that includes a scaffold protein a membrane forming lipid and optionally a target protein. At least one of the scaffold protein and target protein can be provided through an IVT system. The membrane forming lipid, scaffold protein and optionally the target protein can be assembled for a time and under conditions that allow obtaining high yield NLPs, NPLs with an increased solubility, an NLP of a controlled size, and/or an NLP having a size predetermined to include a pre-selected target protein.
Type:
Grant
Filed:
October 12, 2018
Date of Patent:
April 12, 2022
Assignee:
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Inventors:
Matthew A. Coleman, Paul D. Hoeprich, Brent W. Segelke
Abstract: The invention provides polypeptides and encoding nucleic acids of aldehyde dehydrogenase variants. The invention also provides cells expressing aldehyde dehydrogenase variants. The invention further provides methods for producing 3-hydroxybutyraldehyde (3-HBal) and/or 1,3-butanediol (1,3-BDO), or an ester or amide thereof, comprising culturing cells expressing an aldehyde dehydrogenase variant or using lysates of such cells. The invention additional provides methods for producing 4-hydroxybutyraldehyde (4-HBal) and/or 1,4-butanediol (1,4-BDO), or an ester or amide thereof, comprising culturing cells expressing an aldehyde dehydrogenase variant or using lysates of such cells.
Type:
Grant
Filed:
March 29, 2018
Date of Patent:
April 12, 2022
Assignee:
Genomatica, Inc.
Inventors:
Kevin Hoff, Cara Ann Tracewell, Kui Chan, Amit Shah, Joseph Warner, Michael Noble
Abstract: The present disclosure provides compositions and methods for increasing mutation efficiency and homologous recombination rates of site-specific endonucleases. The compositions and methods comprise a chimeric polypeptide comprising a site-specific endonuclease or a domain thereof and a functional moiety. The current inventions relate to functional enhancement of the CRISPR-Cas enzymes. Disclosed herein include possible variants and their intended improvements.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
April 5, 2022
Assignees:
GFLAS LIFE SCIENCES, INC., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Jongjin Park, Ji Young Yoon, Sunmee Choi, Mijin Park, Slki Park, Aiden Y. Park, Jung Hyuk Lee, Junghak Lim, Dong Wook Kim, Sunghwa Choe
Abstract: There is provided method of profiling protein tyrosine phosphorylation of a sample, the method comprising: contacting the sample with an SH2 Superbinder in order to bind pTyr-including peptides contained in the sample with the SH2 Superbinder; isolating the bound pTyr-including peptides from the sample; and identifying the isolated pTyr-including peptides.
Abstract: The present invention relates to prokaryotic host cells and methods for improving expression of a mature protease by co-expression with a propeptide of said protease as two separate polypeptides.
Abstract: The present invention relates to the field of molecular biology and more particularly to promoters useful for metabolic engineering in yeast or fungi for the production of biobased chemicals with broad applications. Intron-containing promoters with strong activity during oil-accumulation stages are particularly useful for genetic engineering in yeast and fungi, particularly Rhodosporidium or Rhodotorula genera. Such promoter are capable of driving strong expression of RNA or proteins in species of the Rhodosporidium or Rhodotorula genera.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
February 22, 2022
Assignee:
Temasek Life Sciences Laboratory Limited
Inventors:
Lianghui Ji, Yanbin Liu, Chong Mei John Koh, Sihui Amy Yap
Abstract: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.
Type:
Grant
Filed:
September 26, 2019
Date of Patent:
February 15, 2022
Assignee:
École Polytechnique Fédérale de Lausanne (EPFL)
Inventors:
Jeffrey A. Hubbell, Stephan Kontos, Karen Y. Dane
Abstract: The present disclosure provides a method of treating seizure in a subject having aberrant alkaline phosphatase activities, comprising administering a therapeutically effective amount of at least one recombinant alkaline phosphatase to the subject.
Type:
Grant
Filed:
October 18, 2019
Date of Patent:
January 18, 2022
Assignee:
Alexion Pharmaceuticals, Inc.
Inventors:
Andre Marozsan, Denise Devore, Susan Liu-Chen
Abstract: An automatic dishwashing cleaning composition having a new protease.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
January 11, 2022
Assignee:
The Procter & Gamble Company
Inventors:
Frits Goedegebuur, David Aaron Estell, Lilia Maria Babe, Thijs Kaper, Viktor Alekseyev, Sina Pricelius, Hatice Billur Engin, Harm Jan Mulder, Sander Van Stigt-Thans, Eva Maria Perez-Prat Vinuesa
Abstract: The present invention relates to a yeast cell, in particular a recombinant yeast cell, the cell lacking enzymatic activity needed for the NADH-dependent glycerol synthesis or the cell having a reduced enzymatic activity with respect to the NADH-dependent glycerol synthesis compared to its corresponding wild-type yeast cell, the cell comprising one or more heterologous nucleic acid sequences encoding an NAD+-dependent acetylating acetaldehyde dehydrogenase (EC 1.2.1.10) activity. The invention further relates to the use of a cell according to the invention in the preparation of ethanol.
Type:
Grant
Filed:
March 27, 2020
Date of Patent:
January 4, 2022
Assignee:
DSM IP ASSETS B.V.
Inventors:
Jacobus Thomas Pronk, Antonius Jeroen Adriaan Van Maris, Victor Gabriel Guadalupe Medina
Abstract: Aspects of the invention include host cells that are engineered to produce benzylisoquinoline alkaloids (BIAs). The host cells include heterologous coding sequences for a variety of enzymes involved in synthetic pathways from starting compounds to BIAs of the host cell. Also provided are methods of producing the BIAs of interest by culturing the host cells under culture conditions that promote expression of enzymes encoded by the heterologous coding sequences of the host cells. Aspects of the invention further include compositions, e.g., host cells, starting compounds and kits, etc., that find use in methods of the invention.
Type:
Grant
Filed:
October 13, 2020
Date of Patent:
January 4, 2022
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Inventors:
Christina D. Smolke, Catherine Thodey, Isis Trenchard, Stephanie Galanie